PolyRemedy Closes Series B Financing, Attracting $25 Million from Leading Venture Capital Firms
PolyRemedy, Inc. is the manufacturer of a robotic system for the delivery of nano-based materials wound dressings. The latest round of financing was co-led by Advanced Technology Ventures (ATV) and IDG Ventures Boston. Series A investors participating included MedVenture Associates and new investor Harris & Harris Group. PolyRemedy was founded by Dr. Oleg Siniaguine, the companyâ€™s Chief Technology Officer and a member of its board of directors. Dr. Siniagiune brings extensive micro-and nano technology and robotic industry knowledge to the company. The PolyRemedy system enables clinicians to both treat and monitor chronic wounds through customized, â€˜smartâ€™ wound dressings that capture and monitor a patientâ€™s condition, thus enabling a targeted and efficient way to treat the patient.